1Singhal S,Mehta J,Diskan R,et al.Antitumor activity of thalidomide in refractory multiple myeloma[J].N Engl J Med,1999,341(21): 1565.
2Palumbo A,Giaeeone L, Bertola A.Low-dose thalidomide plu sdexamethasone is aneffective salvage therapy for advanced myeloma[J].Hematologica,2001,86(4):399.
3Ldidns SH,Muryy T, Bolden S,et al.Cancer statistics[J].CA Cancer J Clic,1999,49:12-13.
2Bellamy W,List A,Grogan T.Expression of VEGF and its receptors in myeloma.Program and abstracts of the Ⅷinternational myeloma workshop[].Canada Reports.2001
3Tosi P,Ronconi S,Zamagni E,et al.Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation[].Haematologica.2001
4Rajkumar S V,Leong T,Roche P C,et al.Prognostic value of bone marrow angiogensis in multiple myeloma[].Clinical Cancer Research.2000
5Schreiber S,Ackermann J,Obermair A,et al.Multiple myeloma with eletion of chromosome 13q is characterized by ineased bone marrow neovascularization[].British Journal of Haematology.2000
6Peuckmann V,Fisch M,Bruera E,et al.Potential novel uses of thalidomide: focus on palliative care[].Drugs.2000
7Celgene.Program and abstracts of the Ⅷinternational myeloma workshop[].Canada Reports.2001
8Faith E D,Noopur R,Teru H,et al.Thalidomide and immunmodulatory derivatives augment natral killer cell cytotoxicity in multiple myeloma[].Blood.2001
9Rajkumar S V,Witzig T E.A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma[].Cancer Treatment Reviews.2000
